Advertisement

Morphea and Scleroderma

  • Rachel Kyllo
  • Martha Laurin CouncilEmail author
Chapter

Abstract

Morphea and scleroderma are a spectrum of autoimmune connective tissue disorders hallmarked by tissue fibrosis. Morphea is localized to the skin, subcutaneous tissues, and occasionally, deeper, directly underlying structures such as muscle and bone. In contrast, scleroderma is characterized by systemic involvement, including the vasculature and internal organs (1a) (Fett, Clin Dermatol 31:432–437, 2013). Treatment largely depends upon the extent of disease, with minor cases of morphea requiring observation and systemic sclerosis requiring potent immunosuppressive medications. Although an exhaustive discussion of medical therapies for this spectrum of diseases is beyond the scope of this chapter, surgeries and laser therapy are important components of comprehensive care of these patients. The cosmetic and functional sequelae of morphea and scleroderma can be extensive, and the procedural dermatologist is in a unique position to reverse some of the manifestations of these debilitating diseases.

Keywords

Morphea En coup de sabre Hemifacial atrophy Scleroderma Raynaud’s Calcinosis Telangiectasias 

References

  1. 1.
    Fett N. Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies. Clin Dermatol. 2013;31(4):432–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc. 1995;70(11):1068–76.PubMedCrossRefGoogle Scholar
  3. 3.
    Fett N, Werth WP. Update on morphea: part 1. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011;64(2):217–28.PubMedCrossRefGoogle Scholar
  4. 4.
    Peterson LS, Nelson AM, Su WP, Mason T, O’Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol. 1997;24:73–80.PubMedGoogle Scholar
  5. 5.
    Zulian F, Athreya BH, Laxer R, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology. 2006;45:612–20.CrossRefGoogle Scholar
  6. 6.
    Leitenberger JJ, Cayce RL, Haley RW, Adams-Hueet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009;145:545–50.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Marzano AV, Menni S, Parodi A, Borghi A, Fuligni A, Fabbri P, et al. Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. Eur J Dermatol. 2003;13:171–6.PubMedGoogle Scholar
  8. 8.
    Mayes MD, Lacey JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D. Prevalence, incidence, survival and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48(8):2246–55.PubMedCrossRefGoogle Scholar
  9. 9.
    Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev. 2010;9(5):A311–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008;37:223–35.PubMedCrossRefGoogle Scholar
  11. 11.
    Mayes MD. Classification and epidemiology of scleroderma. Semin Cutan Med Surg. 1998;17(1):22–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747–55.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Domsic RT. Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement. Curr Opin Rheumatol. 2014;26(6):646–52.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Meier FM, Frommer KW, Dinser R, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2012;71:1355–60.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Mierau R, Moinzadeh P, Riemekasten G, et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features. Arthritis Res Ther. 2011;13:R172.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Varga J. Scleroderma: from pathogenesis to comprehensive management. New York: Springer; 2012.CrossRefGoogle Scholar
  17. 17.
    Winter R. Scleroderma: symptoms, diagnosis and treatment. Hauppauge: Nova Science Publishers; 2013.Google Scholar
  18. 18.
    McCray CJ, Mayes MD. Update on systemic sclerosis. Curr Allergy Asthma Rep. 2015;15(5):25.PubMedCrossRefGoogle Scholar
  19. 19.
    Wigley FM, Flavahan NA. Raynaud’s phenomenon. N Engl J Med. 2016;375:556–65.PubMedCrossRefGoogle Scholar
  20. 20.
    Careta MF, Romiti R. Localized scleroderma: clinical spectrum and therapeutic update. An Bras Dermatol. 2015;90(1):62–73.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Sivek R, Emer J. Use of a blunt-tipped microcannula for soft tissue filler injection in the treatment of linear scleroderma (en coup de sabre). Dermatol Surg. 2014;40(12):1439–41.PubMedCrossRefGoogle Scholar
  22. 22.
    Thareja SK, Sadhwani D, Alan Fenske N. En coup de sabre morphea treated with hyaluronic acid filler. Report of a case and review of the literature. Int J Dermatol. 2015;54(7):823–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Franco JP, Serra MS, Lima RB, D’Acri AM, Martins CJ. Scleroderma en coup de sabre treated with polymethylacrylate – case report. Ann Bras Dermatol. 2016;91(2):209–11.CrossRefGoogle Scholar
  24. 24.
    Al-Niaimi F, Taylor JA, Lyon CC. Idiopathic hemifacial atrophy treated with permanent polyacrylamide subdermal filler. Dermatol Surg. 2012;38(11):143–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Ibler KS, Gramkow C, Siemssen PA. Autologous fat transplantation for the treatment of linear scleroderma en coup de sabre. Skinmed. 2015;13(1):74–6.PubMedGoogle Scholar
  26. 26.
    Consorti G, Tieghi R, Clauser L. Frontal linear scleroderma: long-term result in volumetric restoration of the fronto-orbital area by structural fat grafting. J Craniofac Surg. 2012;23:e263–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Lapiere JC, Aasi S, Cook B, Montalvo A. Successful correction of depressed scars of the forehead secondary to trauma and morphea en coup de sabre by en bloc autologous dermal fat graft. Dermatol Surg. 2000;26(8):793–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Mertens JS, Seyger MM, Kievit W, Hoppenreijs EP, Jansen TL, van de Kerkhof PC, Radstake TR, de Jong EM. Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric- or adult-onset disease. Br J Dermatol. 2015;172(3):722–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Choksi AN, Orringer JS. Linear morphea-induced atrophy treated with hyaluronic acid filler injections. Dermatol Surg. 2011;37(6):880–3.PubMedGoogle Scholar
  30. 30.
    Barin EZ, Cinal H, Cakmak MA, Tan O. Treatment of linear scleroderma (en coup de sabre) with dermal fat grafting. J Cutan Med Surg. 2016;20(3):269–71.PubMedCrossRefGoogle Scholar
  31. 31.
    Roh MR, Jung JY, Chung KY. Autologous fat transplantation for depressed linear scleroderma-induced facial scars. Dermatol Surg. 2008;34(12):1659–65.PubMedGoogle Scholar
  32. 32.
    Shiffman MA. Autologous fat transfer: art, science, and clinical practice. Berlin/Heidelberg: Springer; 2010.CrossRefGoogle Scholar
  33. 33.
    Cavusoglu T, Yazici I, Vargel I, Karakaya EI. Reconstruction of coup de sabre deformity (linear localized scleroderma) by using galeal frontalis muscle flap and demineralized bone matrix combination. J Plast Reconstr Aesthet Surg. 2009;62(2):e25–8.CrossRefGoogle Scholar
  34. 34.
    Baek R, Heo C, Kim BK. Use of various free flaps in progressive hemifacial atrophy. J Craniofac Surg. 2011;22(6):2268–71.PubMedCrossRefGoogle Scholar
  35. 35.
    Danino AM, Ichinose M, Yoshimoto S, Wako M, Servant JM. Repair of wide coup de sabre without cutaneous excision by means of pericranial-galeal padding flap. Plast Reconstr Surg. 1999;104(7):2108–11.PubMedCrossRefGoogle Scholar
  36. 36.
    Agostini T, Spinelli G, Marino G, Perello R. Esthetic restoration in progressive hemifacial atrophy (Romberg disease): structural fat grafting versus local/free flaps. J Craniofac Surg. 2014;25(3):783–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Sengezer M, Deveci M, Selmanpakoglu N. Repair of “coup de sabre,” a linear form of scleroderma. Ann Plast Surg. 1996;37(4):428–32.PubMedCrossRefGoogle Scholar
  38. 38.
    Hwang DY, Paik HW, Byeon JH. Correction of facial linear scleroderma ‘coup de sabre’ with BoneSource. J Craniofac Surg. 2012;23(3):e263–5.CrossRefGoogle Scholar
  39. 39.
    Slack GC, Tabit CJ, Allam KA, Kawamoto HK, Bradley JP. Parry-Romberg reconstruction: optimal timing for hard and soft tissue procedures. J Craniofac Surg. 2012;23(7):1969–73.PubMedGoogle Scholar
  40. 40.
    Chung L, Fiorentio D. Digital ulcers in patients with systemic sclerosis. Autoimmun Rev. 2006;5(2):125–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum. 2002;46(9):2410–20.PubMedCrossRefGoogle Scholar
  42. 42.
    Ferri C, Valentini G, Cozi F, Sebastiani M, Michelassi C, La MG, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine. 2002;81(2):139–53.PubMedCrossRefGoogle Scholar
  43. 43.
    Flavahan NA. A vascular mechanistic approach to understanding Raynaud phenomenon. Nat Rev Rheumatol. 2015;11:146–58.PubMedCrossRefGoogle Scholar
  44. 44.
    Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum. 2001;44:1841–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2013;72:1696–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Engelhart M. The effect of sympathetic blockade and cooling in Raynaud’s phenomenon. Clin Physiol. 1990;10(2):131–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Klyscz T, Junger M, Meyer H, Rassner G. Improvement of acral circulation in a patient with systemic sclerosis with stellate blocks. Vasa. 1998;27(1):39–42.PubMedGoogle Scholar
  48. 48.
    Omote K, Kawamata M, Namiki A. Adverse effects of stellate ganglion block on Raynaud’s phenomenon associated with progressive systemic sclerosis. Anesth Analg. 1993;77(5):1057–60. EnPubMedCrossRefGoogle Scholar
  49. 49.
    Coveliers HM, Hoexum F, Nederhoed JH, Wisselink W, Rauwerda JA. Thoracic sympathectomy for digital ischemia: a summary of evidence. J Vasc Surg. 2011;54(1):273–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Wasserman A, Brahn E. Systemic sclerosis: bilateral improvement of Raynaud’s phenomenon with unilateral digital sympathectomy. Semin Arthritis Rheum. 2010;40(2):137–46.PubMedCrossRefGoogle Scholar
  51. 51.
    Kotsis SV, Chung KC. A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia. J Rheumatol. 2003;30(8):1788–92.PubMedGoogle Scholar
  52. 52.
    Merritt WH. Role and rationale for extended periarterial sympathectomy in the management of severe Raynaud syndrome: techniques and results. Hand Clin. 2015;31(1):101–20.PubMedCrossRefGoogle Scholar
  53. 53.
    Stone AV, Koman LA, Callahan MF, Eckman DM, Smith BP, Plate JF, Smith TL. The effect of botulinum neurotoxin-A on blood flow in rats: a potential mechanism for treatment of Raynaud phenomenon. J Hand Surg Am. 2012;37(4):795–802.PubMedCrossRefGoogle Scholar
  54. 54.
    Uppal L, Dhaliwal K, Butler PE. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud’s syndrome associated with scleroderma. J Hand Surg Eur. 2014;39:876–80.CrossRefGoogle Scholar
  55. 55.
    Zebryk P, Puszczewicz MJ. Botulinum toxin A in the treatment of Raynaud’s phenomenon: a systematic review. Arch Med Sci. 2016;12(4):864–70.PubMedCrossRefGoogle Scholar
  56. 56.
    Van Beek AL, Lim PK, Gear AJ, et al. Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg. 2007;119:217–26.PubMedCrossRefGoogle Scholar
  57. 57.
    Fregene A, Ditmars D, Siddiqui A. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud’s phenomenon. J Hand Surg Am. 2009;34:446–52.PubMedCrossRefGoogle Scholar
  58. 58.
    Neumeister MW. Botulinum toxin type A in the treatment of Raynaud’s phenomenon. J Hand Surg Am. 2010;35:2085–92.PubMedCrossRefGoogle Scholar
  59. 59.
    Serri J, Legre R, Veit V, et al. Botulinum toxin type A contribution in the treatment of Raynaud’s phenomenon due to systemic sclerosis. Ann Chir Plast Esthet. 2013;58:658–62.PubMedCrossRefGoogle Scholar
  60. 60.
    Daoussis D, Antonopoulos I, Liossis SN, Yiannopoulos G, Andonopoulos AP. Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum. 2012;41(6):822–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E. Calcinosis cutis: part II. Treatment options. J Am Acad Dermatol. 2011;65(1):15–22.PubMedCrossRefGoogle Scholar
  62. 62.
    Saddic N, Miller JJ, Miller OF 3rd, Clarke JT. Surgical debridement of painful fingertip calcinosis cutis in CREST syndrome. Arch Dermatol. 2009;145(2):212–3.PubMedCrossRefGoogle Scholar
  63. 63.
    Bogoch ER, Gross DK. Surgery of the hand in patients with systemic sclerosis: outcomes and considerations. J Rheumatol. 2005;32(4):642–8.PubMedGoogle Scholar
  64. 64.
    Chamberlain AJ, Walker NP. Successful palliation and significant remission of cutaneous calcinosis in CREST syndrome with carbon dioxide laser. Dermatol Surg. 2003;29(9):968–70.PubMedGoogle Scholar
  65. 65.
    Bottomley WW, Goodfield MJ, Sheehan-Dare RA. Digital calcification in systemic sclerosis: effective treatment with good tissue preservation using the carbon dioxide laser. Br J Dermatol. 1996;135(2):302–4.PubMedCrossRefGoogle Scholar
  66. 66.
    Sparsa A, Lesaux N, Kessler E, Bonnetblanc JM, Blaise S, Lebrun-Ly V, et al. Treatment of cutaneous calcinosis in CREST syndrome by extracorporeal shock wave lithotripsy. J Am Acad Dermatol. 2005;53(5):S263–5.PubMedCrossRefGoogle Scholar
  67. 67.
    Sultan-Bichat N, Menard J, Perceau G, Staerman F, Bernard P, Reguiai Z. Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy. J Am Acad Dermatol. 2012;66(3):424–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Ciatti S, Varga J, Greenbaum SS. The 585 nm flashlamp-pumped pulsed dye laser for the treatment of telangiectasias in patients with scleroderma. J Am Acad Dermatol. 1996;35(3):487–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Halachmi S, Gabari O, Cohen S, Koren R, Amitai DB, Lapidoth M. Telangiectasias in CREST syndrome and systemic sclerosis: correlation of clinical and pathological features with response to pulsed dye laser treatment. Lasers Med Sci. 2014;29(1):137–40.PubMedCrossRefGoogle Scholar
  70. 70.
    Murray AK, Moore TL, Richards H, Ennis H, Griffiths CE, Herrick AL. Pilot study of intense pulsed light for the treatment of systemic sclerosis-related telangiectasias. Br J Dermatol. 2012;167(3):563–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Dinsdale G, Murray A, Moore T, Ferguson J, Wilkinson J, Richards H, et al. A comparison of intense pulsed light and laser treatment of telangiectasias in patients with systemic sclerosis: a within-subject randomized trial. Rheumatology (Oxford). 2014;53(8):1422–30.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of DermatologyNorthwestern University Feinberg School of MedicineChicagoUSA
  2. 2.Division of Dermatology, Department of Internal MedicineWashington University School of MedicineSt. LouisUSA

Personalised recommendations